During a press conference Tuesday at the International AIDS Conference in Vienna, Anthony Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases at NIH, describes the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial. The study is testing the safety and efficacy of microbicide gel containing the ARV drug tenofovir, and oral tablets containing tenofovir or a combination of tenofovir and emtricitabine known by the brand name Truvada.
By Felix Chinguwo A two-year program in Malawi aims to educate people, especially men and boys, about HIV, reduce transmission of the virus, help people to […]
CDC announces publication of TB treatment trial results showing four month regimen as effective as six month
The publication of trial data showing a four-month treatment regimen for tuberculosis that is not resistant to first-line medicines as effective as the currently widely prescribed […]
By Mitchell Warren, executive director, AVAC In February 2020, just as the COVID pandemic began its rapid global spread, a major HIV vaccine trial called HVTN […]
By Amir M. Mohareb, MD, Louise C. Ivers, MD, MPH, Rajesh T. Gandhi, MD, and Shahin Lockman, MD, MSc As the U.S. convenes a global COVID-19 […]